The terms, per the grant. On March 23, 2021, The Broad Institute was issued US10954514B2, covering escorted and functionalized guide RNAs for CRISPR-Cas systems. The CPC tags — C12N 15/111 (modified RNA), C12N 9/22 (nucleases), and C12N 2320/32 (delivery) — describe engineered guides, an improvement layer on top of the base editing machinery.
Why a deals desk treats this estate as load-bearing: the foundational CRISPR patents — and the long-running ownership questions around them — are the backdrop to every gene-editing deal. A licensee's freedom to operate, and therefore the value of its programs, depends on how it stands relative to estates like the Broad's. Functionalized-guide IP adds a second layer of claims a competitor must navigate.
The structure point: improvement patents like engineered guides can be licensed alongside or independently of foundational claims, and they extend the protective period around a platform. For a deal model, they are the difference between a moat that ends at the base patent and one that keeps refreshing with each engineering advance.
What the grant does not resolve: it does not by itself decide who owns foundational CRISPR, nor does it guarantee any program's clinical success. It is an exclusivity claim on a class of engineered guides — a real asset, but one that sits within a contested and crowded estate.
The takeaway: when a gene-editing deal crosses the desk, map the licensee against the foundational estates first, then read the improvement grants. The Broad's March 2021 functionalized-guide grant is a dated example of the layered IP that defines CRISPR platform value.